MedTrace Logo

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

NCT05272826 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2026-03-18

No results posted yet for this study

Summary

This study will evaluate efficacy and tolerability of iberdomide, bortezomib, dexamethasone and isatuximab on demand administered in combination for newly diagnosed transplant-ineligible multiple myeloma patients.

Conditions

Interventions

DRUG

Iberdomide

Available as formulated capsules and administered as oral medication

DRUG

Bortezomib

Administered as subcutaneous injection

DRUG

Dexamethasone

Administered as oral medication

DRUG

Isatuximab

Administered as subcutaneous injection

Sponsors & Collaborators

  • Canadian Myeloma Research Group

    lead OTHER

Principal Investigators

  • Martha Louzada, MD, MSc · London Health Sciences Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-12
Primary Completion
2028-03-31
Completion
2031-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272826 on ClinicalTrials.gov